A randomized, open-label study of the effect of PEGASYS [peginterferon alfa-2a] versus Roferon-A (Interferon alfa-2a, Recombinant) on cytogenetic response in patients with chronic myelogenous leukemia

Trial Profile

A randomized, open-label study of the effect of PEGASYS [peginterferon alfa-2a] versus Roferon-A (Interferon alfa-2a, Recombinant) on cytogenetic response in patients with chronic myelogenous leukemia

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2010

At a glance

  • Drugs Interferon alpha-2a; Peginterferon alfa-2a
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 24 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top